OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Interactive ToolsLearning ModulesPresentationsSponsored
Biomarker Consortium
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • 2024 nominations are open for Giants of Cancer Care®
  • In-person and virtual events just for HCPs
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
    • Biomarker Consortium
Advertisement

Dr. Verstovsek Discusses Research Efforts in Myelofibrosis-Related Anemia

September 10, 2021
Srdan Verstovsek, MD, PhD
Video
Conference|Society of Hematologic Oncology Annual Meeting (SOHO)

Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.

Srdan Verstovsek, MD, PhD, United Energy Resources, Inc. Professor of Medicine, director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms, chief, Section for Myeloproliferative Neoplasms, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research in myelofibrosis-related anemia.

Although JAK inhibitors are effective treatments for reducing splenomegaly and controlling symptoms in myelofibrosis, anemia remains a challenge for this patient population, Verstovsek explains. As such, novel therapies are in development with the goal of treating anemia in myelofibrosis.

Luspatercept-aamt (Reblozyl) is being evaluated in the ongoing phase 3 INDEPENDENCE trial (NCT04717414) vs placebo in patients with myeloproliferative neoplasm–associated myelofibrosis who are receiving JAK inhibitor therapy and requiring red blood transfusions. Combining luspatercept with JAK inhibitors, such as ruxolitinib (Jakafi), could improve anemia while decreasing splenomegaly and controlling symptoms, Verstovsek says.

Notably, anemia remains the leading cause of ruxolitinib discontinuation in myelofibrosis, so patients requiring treatment in the second-line setting often have a much higher degree of anemia or thrombocytopenia compared with patients in the frontline setting, Verstovsek says. In the second-line setting, momelotinib is being evaluated in comparison with danazol for symptomatic and anemic patients with myelofibrosis previously treated with a JAK inhibitor in the phase 3 MOMENTUM trial (NCT04173494), Verstovsek concludes.

Related Videos
Susan Bal, MD
Paolo Ghia, MD, PhD
Michael R. Cook, MD
Andre Goy, MD
Peter Schmid, MD, PhD
Seema A. Khan, MD
Stephanie L. Graff, MD
Senthil Damodaran, MD, PhD
Jason Jincong Freeman, PhD
Heather A. Parsons, MD, MPH
Related Content
Advertisement
Daniel Wolff, MD, PhD, of the University Hospital of Regensburg in Germany,

Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD

December 11th 2023
Article
Ecaterina E. Dumbrava, MD

Dumbrava Details Ongoing Research With PC14586 in p53 Y220C–Mutated Advanced Solid Tumors

November 23rd 2023
Podcast
Sabarish Ram Ayyappan, MD

Odronextamab Exhibits Continued Clinical Activity and Tolerable Safety Profile in R/R DLBCL

December 10th 2023
Article
Courtney D. DiNardo, MD, MSCE

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

November 20th 2023
Podcast
Mazyar Shadman, MD, MPH

Retrospective Analysis Supports Utilization of Auto-HCT in Relapsed LBCL Achieving a CR

December 10th 2023
Article
Claire Roddie, MD, of University College London

Obe-Cel Elicits High Remission Rates in R/R B-ALL Irrespective of Leukemic Burden

December 10th 2023
Article
Related Content
Advertisement
Daniel Wolff, MD, PhD, of the University Hospital of Regensburg in Germany,

Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD

December 11th 2023
Article
Ecaterina E. Dumbrava, MD

Dumbrava Details Ongoing Research With PC14586 in p53 Y220C–Mutated Advanced Solid Tumors

November 23rd 2023
Podcast
Sabarish Ram Ayyappan, MD

Odronextamab Exhibits Continued Clinical Activity and Tolerable Safety Profile in R/R DLBCL

December 10th 2023
Article
Courtney D. DiNardo, MD, MSCE

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

November 20th 2023
Podcast
Mazyar Shadman, MD, MPH

Retrospective Analysis Supports Utilization of Auto-HCT in Relapsed LBCL Achieving a CR

December 10th 2023
Article
Claire Roddie, MD, of University College London

Obe-Cel Elicits High Remission Rates in R/R B-ALL Irrespective of Leukemic Burden

December 10th 2023
Article

Latest Conference Coverage

Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD

Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma

Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL

Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact